BRAF and neoplasm: While patients in SECOMBIT all had advanced melanoma, the short course of BRAF inhibition in Arm C may have shifted the immune infiltrate toward dominance of newly activated effector T cells by normalizing the vasculature, debulking the tumor, increasing glucose availability58,59, and alleviating hypoxia60.